Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
1.715    0.025 (1.48%)
Bid:
1.50
Ask:
1.93
Spread: 0.43 (28.667%)
Market Cap: £5.93m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

Directorate Change

1 Jul 2014 07:00

RNS Number : 9952K
Proteome Sciences PLC
01 July 2014
 



 

 

 

 

 

PRESS RELEASE

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Appointment of Roger McDowell as Non-Executive Director

 

1st July, 2014 Proteome Sciences is pleased to announce the appointment of Roger Steven McDowell to the Board of the Company as a non-executive Director with immediate effect.

 

Roger McDowell has a highly successful career as a businessman and entrepreneur. He was Managing Director of Oliver Ashworth for eighteen years before its sale to St. Gobain. He is currently the Chairman or a non-executive director of seven listed companies, namely Avingtrans plc, Servelec Group plc, Renovo plc, Alkane Energy plc, Swallowfield plc, IS Solutions plc and Augean plc. He brings considerable commercial experience with him and is a keen exponent of growing shareholder value.

 

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Roger Steven McDowell, age 60 years, is or has been a director of the following companies during the five years preceding the date of this announcement:

 

Current directorships Past directorships

Corsair Techinvest Ltd One Advice Group plc

Fineguard Ltd Ultimate Finance Group plc

Augean plc

Disperse Ltd

Dovehoco 201 Ltd

Avingtrans plc

IS Solutions plc

Swallowfield plc

Alkane Energy plc

Renovo plc

Servelec Group plc

 

There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies. 

 

At the AGM, held on 30 June 2014, it was announced that Steve Harris, the Chairman, was proposing to retire and he has now formally stepped down as a director.

 

The Board of Proteome Sciences would like to thank him for the considerable contribution and support that he has provided to the Company over the last 20 years, a period in which the Company's outstanding biomarker research has been converted into products, services and commercial revenue. We wish him a long and enjoyable retirement.

 

The CEO, Christopher Pearce, has been appointed Executive Chairman. Dr. Ian Pike remains the Chief Operating Officer.

 

 

- Ends -

 

 

 

 

 

 

For further information please contact:

Proteome Sciences plc

Christopher Pearce, Chief Executive Officer

Tel: +44 (0)1932 865065

Dr. Ian Pike, Chief Operating Officer

James Malthouse, Finance Director

Nominated Adviser

Cenkos

Stephen Keys/Callum Davidson

Tel: +44 (0)20 7397 8900

Public Relations

IKON Associates

Adrian Shaw

Tel: +44 (0)1483 271291

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAKBLFXZQFEBBD
Date   Source Headline
1st Apr 20217:40 amRNSFinal Results
30th Mar 20217:00 amRNSLoan Amendment
29th Mar 20216:21 pmRNSHolding(s) in Company
26th Mar 20217:00 amRNSTrading Update and Notice of Results
25th Jan 20217:00 amRNSYear End Trading Update
18th Jan 20217:00 amRNSHolding(s) in Company
15th Sep 20204:35 pmRNSDirector/PDMR Shareholding
14th Sep 20207:00 amRNSAppointment of Chief Executive Officer
10th Aug 20207:00 amRNSInterim Results
27th Jul 202011:53 amRNSHolding(s) in Company
7th Jul 20201:47 pmRNSDirector/PDMR Shareholding
2nd Jul 20204:08 pmRNSDirector/PDMR Shareholding
26th Jun 202011:45 amRNSResult of AGM
26th Jun 202011:00 amRNSAGM Statement
2nd Jun 20207:00 amRNSNotice of Annual General Meeting
30th Apr 20204:53 pmRNSHolding(s) in Company
28th Apr 202011:16 amRNSResponse to Share Price Movement
20th Apr 20207:00 amRNSPosting of Results, AGM update and loan amendment
14th Apr 20207:00 amRNSFinal Results
30th Mar 20207:00 amRNSNotice of Results
16th Mar 20207:00 amRNSNotice of Results
3rd Mar 20207:00 amRNSDirector/PDMR Shareholding
11th Feb 20207:00 amRNSFurther Year End Trading Update, Milestone Payment
21st Jan 20207:00 amRNSYear End Trading Update
31st Oct 20197:00 amRNSTrading Update and Announcement of Board Changes
25th Jul 20197:00 amRNSInterim Results
1st Jul 20197:00 amRNSLaunch of new services powered by TMTpro 16plex
30th Apr 20193:44 pmRNSResult of AGM
30th Apr 20192:30 pmRNSAGM Statement and Q1 Trading Update
2nd Apr 20197:00 amRNSResults and Notice of AGM
14th Mar 20197:00 amRNSNotice of Results
23rd Jan 20197:00 amRNSYear End Trading Update
20th Dec 20187:00 amRNSAppointment of Nominated Adviser and Broker
10th Dec 20189:26 amRNSHolding(s) in Company
26th Nov 20184:38 pmRNSDirector/PDMR Shareholding
23rd Nov 20181:26 pmRNSDirector/PDMR Shareholding
21st Nov 20189:41 amRNSDirector/PDMR Shareholding
16th Nov 20182:35 pmRNSDirector/PDMR Shareholding
14th Nov 201812:10 pmRNSDirector/PDMR Shareholding
9th Nov 20184:34 pmRNSDirector/PDMR Shareholding
6th Nov 20187:00 amRNSTrading Update
12th Oct 20184:43 pmRNSDirector/PDMR Shareholding
9th Oct 20183:28 pmRNSDirector/PDMR Shareholding
8th Oct 201810:31 amRNSBlock listing Interim Review
4th Oct 20181:42 pmRNSDirector/PDMR Shareholding
1st Oct 20183:39 pmRNSDirector/PDMR Shareholding
21st Sep 20185:10 pmRNSDirector/PDMR Shareholding
12th Sep 20184:18 pmRNSDirector/PDMR Shareholding
7th Sep 20183:43 pmRNSDirector/PDMR Shareholding
14th Aug 201810:04 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.